

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Terre Haute Regional Hospital</p>	<p>In accordance with letter dated September 22, 2016,</p>	<p>4. Expiration Date: June 30, 2021</p>	
<p>2. 3901 South Seventh Street Terre Haute, IN 47802</p>	<p>3. License number: 13-09649-02 is amended in its entirety to read as follows:</p>	<p>5. Docket No.: 030-09540 Reference No.:</p>	
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Palladium-103</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed Sources (Best Medical International, Inc., Model 2335; Theragenics Corporation, Model TheraSeed 200)</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>C. 1 curie total</p> <p>D. 1 curie total</p>	<p>9. Authorized use</p> <p>A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.</p> <p>B. Any imaging and localization study permitted by 10 CFR 35.200.</p> <p>C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.</p> <p>D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.</p>




**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
13-09649-02

Docket or Reference Number  
030-09540

Amendment No. 67

- |   |   |  |   |
|---|---|--|---|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form  | 8. Maximum amount that licensee may possess at any one time under this license | 9. Authorized use   |
| E. Iodine-125   | E. Sealed Sources (Medi-Physics Inc., Model 6711 (OncoSeed); Theragenics Corporation, Model I-Seed AgX100)  | E. 1 curie total   | E. Any manual brachytherapy procedure permitted by 10 CFR 35.400. |
| F. Iridium-192  | F. Sealed Sources (Best Medical International, Inc., Model 81-01)   | F. 1 curie total   | F. Any manual brachytherapy procedure permitted by 10 CFR 35.400. |
| G. Cesium-137   | G. Sealed Sources (3M Health Physics Service, Model 6590 Series; 6520 Series; AEA Technology, Model CDC.T1) | G. 1 curie total   | G. Any manual brachytherapy procedure permitted by 10 CFR 35.400. |
| H. Any byproduct material permitted by 10 CFR 31.11   | H. Prepackaged Kits   | H. 2 millicuries total   | H. In vitro studies.  |



10. A. Licensed material may be used only at the licensee's facilities located at 3901 South Seventh Street, Terre Haute, Indiana.  
 B. Licensed material listed in Subitem Nos. 6.A., 6.B., and 6.C. may also be used at the licensee's facilities located at 135 East McCallister Drive, Terre Haute, Indiana.
11. The Radiation Safety Officer (RSO) for this license is Edward Johnston III.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
13-09649-02

Docket or Reference Number  
030-09540


Amendment No. 67

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User(M.D.,D.O.,etc.)

Material and Use

Thomas M. Schmitz, M.D.	10 CFR 35.100 and 35.200.
Edward R. Bartley, M.D.	10 CFR 35.100 and 35.200.
Eric D. Elliott, M.D.	10 CFR 35.100 and 35.200.
Steve A Fritsch, M.D.	10 CFR 35.100 and 35.200.
John A Morton, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
Brian J. Wiegel, M.D.	10 CFR 35.100, 35.200 and 35.300.
Peter D. Arfken, M.D.	10 CFR 35.100, 35.200 and 35.300.
Homer F. Beltz, M.D.	10 CFR 35.100 and 35.200.
Theodore P. Labus, M.D.	10 CFR 35.100, 35.200 and 35.300.
Charles A. Lerner, M.D.	10 CFR 35.100 and 35.200.
Michael S. Skulski, M.D.	10 CFR 35.100 and 35.200.
Margaret Brengle, M.D.	10 CFR 35.100 and 35.200.
Janalyn P. Ferguson, M.D.	10 CFR 35.100 and 35.200.
Jack J. Moss, M.D.	10 CFR 35.100 and 35.200.
Lori J. Wells, M.D.	10 CFR 35.100 and 35.200.
Thomas Hagman, M.D.	10 CFR 35.100, 35.200 and 35.300.
J. Michael Phelps, Jr., M.D.	10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries).
Timothy L. Davis, M.D.	10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries).
John Mark Michael, M.D.	10 CFR 35.100, 35.200 and 35.300.
Frank J. Pistoia, M.D.	10 CFR 35.100 and 35.200.
Cristina N. Shinaver, M.D.	10 CFR 35.100, 35.200 and 35.300.
Richard L. Hallet, M.D.	10 CFR 35.100, 35.200 and 35.300.



**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
13-09649-02

Docket or Reference Number  
030-09540

Amendment No. 67

Authorized User(M.D.,D.O.,etc.)

Caryn Cockerill Anderson, M.D.

Warren Kent Hansen, M.D.

Carlo Roberto Lazzaro, M.D.

Jane S. Mitchell, M.D.

David R. Gulliver, M.D.

Jeffrey I. Reider, M.D.

Laura Dugan, M.D.

Eric E. Beltz, M.D.

Michael S. Conley, M.D.

Charles C. Mulry, M.D.

Patricia Ellen Ladd, M.D.

Marc P. Underhill, M.D.

Vincent L. Flanders, M.D.

Stewart Stivers Worrell, M.D.

Andrew J. Sundblad, M.D.

Martha Dwenger, M.D.

Ryan N. Sauer, M.D.

Larry L. Stover, M.D.

Kelly K. Horst, M.D.

Material and Use

10 CFR 35.100 and 35.200.

10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries).

10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries).

10 CFR 35.100 and 35.200.

10 CFR 35.100, 35.200 and 35.300

10 CFR 35.100 and 35.200.

10 CFR 35.100 and 35.200.

10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries).

10 CFR 35.100 and 35.200.

10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries).

10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries).

10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries).

10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries).

10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries).


10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131).

10 CFR 35.100, 35.200 and 35.300.

10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131).

10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131).

10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131).



**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

 License Number  
13-09649-02

 Docket or Reference Number  
030-09540

Amendment No. 67

Authorized User(M.D.,D.O.,etc.)


 Parin Bhayani, M.D.  
 Matthew M Jones, M.D.  
 Matthew Locker, M.D.  
 Joshua D. Dowell, M.D.  
 Shrey K. Thawait, M.D.

Material and Use

 10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131).  
 10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131).  
 10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131).  
 10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131).  
 10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131).

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Letter dated February 2, 2011 (ML110380167)  
 B. Letter dated April 1, 2012 (ML13101A396)  
 C. Letter dated October 22, 2015 (ML15309A734)  
 D. Letter dated November 23, 2015 (ML15336A453)


 Date: December 28, 2016

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

By:

 Colleen Carol Casey  
 Region 3